United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 31st. The shares were sold at an average price of $261.50, for a total transaction of $2,092,000.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,995. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $252.80 on Friday. The stock has a market cap of $11.52 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 1.85 and a beta of 0.63. The firm’s fifty day simple moving average is $270.06 and its 200 day simple moving average is $242.68. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $283.09. The company has a quick ratio of 9.39, a current ratio of 9.68 and a debt-to-equity ratio of 0.18.
United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analysts’ expectations of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. As a group, research analysts predict that United Therapeutics Co. will post 16.58 EPS for the current year.
Institutional Trading of United Therapeutics
Analyst Ratings Changes
A number of research firms have recently commented on UTHR. UBS Group began coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price objective for the company. Argus lifted their target price on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, January 11th. Morgan Stanley lifted their target price on shares of United Therapeutics from $322.00 to $330.00 and gave the company an “overweight” rating in a research report on Tuesday, December 6th. Wedbush lifted their target price on shares of United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.64.
United Therapeutics Company Profile
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.